

Increased PD-L1 expression may be associated with the cytokine storm and CD8⁺ T-cell exhaustion in severe COVID-19

Jiezhong Chen¹ and Luis Vitetta^{1,2}

1. Research Department, Medlab Clinical, Sydney 2015, Australia
2. Faculty of Medicine and Health, The University of Sydney, Sydney 2006, Australia

Corresponding

Dr. Jiezhong Chen Email: Jiezhong_chen@medlab.co

Professor Luis Vitetta Email: luis_vitetta@medlab.co and luis.vitetta@sydney.edu.au and

Key words: cytokine storm, signalling pathways, PD-L1, CD8⁺ T-cell exhaustion

Severe Covid-19 is characterised by both a cytokine storm and lymphopenia with reduced frequency of CD4⁺ and CD8⁺ T-cells [1]. CD8⁺ cytotoxic T-lymphocyte cells play a key role in virus clearance, thereby decreasing viral replication and viral load [2]. Numerous clinical studies have characterized the changes of CD8⁺ T-cells in mild and severe COVID-19 patients that expose the importance of CD8⁺ T-cells in the progression of Covid-19. However, the mechanisms by which the changes in CD8⁺ T-cells that ensue are not well elucidated. The study by Vitte et al found that increased PD-L1 in basophils, eosinophils, monocytes and NK cells in severe COVID-19 patients, particularly the expression of PD-L1 in basophils and eosinophils, were correlated with COVID-19 severity [3]. These findings could provide a plausible explanation for CD8⁺ T-cell exhaustion in COVID-19. The cytokine storm may be responsible for increased PD-L1 expression, which leads to CD8⁺ T-cell exhaustion. However, the study failed to identify the importance of lymphopenia in COVID-19 severity, probably due to small sample numbers (89% in severe cases vs 71% in mild cases, not statistically significant). Similarly, the cytokine storm was also not well characterized and correlated with PD-L1 expression in severe COVID-19.

In severe COVID-19, blood levels of proinflammatory cytokines such as IL-6, IL-17 and TNF-alpha are significantly increased together with increased activity of macrophages and neutrophils [4]. These cytokines could be the cause for the increased expression of PD-L1 on the surfaces of immune cells in COVID-19. It is well known that PD-L1 expression is regulated by various signalling pathways which are activated by proinflammatory cytokines (Fig. 1)[5]. For example, IL-6 can activate the STAT3 signalling pathway, which in turn increases the expression of PD-L1[5]. TNF-alpha can activate PI3K/Akt and NF-kB signalling pathways that also upregulate PD-L1 expression. These cytokines may have a synergistic effect on the expression of PD-L1. The PD-L1/PD-1 axis is a major regulator of CD8⁺ T-cell functionalities and survivability. PD-L1 binds to and activates PD-1, resulting in CD8⁺ T-cell dysfunction and apoptosis [5].

Elucidation of a cytokine storm/PD-L1/PD-1/CD8 T-cell exhaustion axis may have important therapeutic implications. Inhibition of proinflammatory cytokines and activated signalling pathways that increase expression of checkpoint molecules may also be effective for recovering CD8⁺ T-cells (Fig. 1). A recent study has correlated pro-inflammatory cytokines with changes of CD8⁺ T-cells in COVID-19 [6]. Furthermore, anti-IL-6 treatment of COVID-19 patients increased CD8⁺ T-cell frequency and functionalities [7]. In addition, blockade of PD-L1/PD-1 could be an approach that recovers CD8⁺ T-cell numbers and functionalities. Also, anti-inflammatory cytokines may be used to decrease the inflammatory status and recover CD8⁺ T-cells. For example, IL-15 has been proposed for the treatment of COVID-19 [4]. IL-15 can increase CD8⁺ T-cell functionalities, CD8⁺ memory T-cells and “memory-like” naive CD8⁺ T-cells [8, 9]. While additional studies are required to further understand the mechanisms of CD8⁺ T-cell exhaustion, it is plausible that approaches that target pro-inflammatory cytokines, activated signals, PD-L1/PD-1 could significantly contribute to the recovery of the repertoire of CD8⁺ T-cells in fulminant Covid-19 cases (Fig. 1).

Accepted Manuscript

Figure Legend

Fig. 1 Pro-inflammatory cytokines and PD-L1/PD-1 axis in severe COVID-19

Pro-inflammatory cytokines bind to their receptors on immune cells to produce positive signals, which increase expression of PD-L1. PD-L1 binds to PD-1 on CD8⁺ T-cell to produce inhibitory signals, which block the function of CD8⁺ T-cells to secrete perforin and granzyme B as well as cause apoptosis of CD8⁺ T-cells. Blockades of pro-inflammatory cytokines, activated signalling pathways and immune check point proteins could be therapeutic options. Abbreviations: PD-L1, programmed death ligand-1; PD-1, programmed cell death protein-1.

Accepted Manuscript

Funding

We received no external funds for this work.

Conflicts of interest

We declare that we have no conflicts of interest.

Accepted Manuscript

References

1. Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell*. **2020**;181(5):1036-1045.
2. Kaech SM, and Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. *Nat. Rev. Immunol.* **2012**;12:749-61.
3. Vitte J, Diallo AB, Boumaza A et al. A granulocytic signature identifies COVID-19 and its severity. *J Infect Dis.* **2020**; 222(12):1985-1996.
4. Kandikattu HK, Venkateshaiah SU, Kumar S, et al. IL-15 immunotherapy is a viable strategy for COVID-19. *Cytokine Growth Factor Rev.* **2020**; 54:24-31.
5. Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. *Ann. Oncol.* **2016**; 27:409-416.
6. Mazzone A, Salvati L, Maggi L, et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. *J Clin Invest.* **2020**; 130(9):4694-4703.
7. Guo C, Li B, Ma H, et al. Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm. *Nat Commun.* **2020**; 11:3924.
8. Condotta SA, Rai D, James BR, et al. Sustained and incomplete recovery of naïve CD8 T cell precursors after sepsis contributes T cell responses to infection. *J Immunol.* **2013**; 190:1991-2000.
9. Nolz JC, Richer MJ. Control of memory CD8 T cell longevity and effector function by IL-15. *Mol Immunol.* **2020**; 117:180-188.

Figure 1

